Panbela Therapeutics Receivables 2020-2024 | PBLA

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Panbela Therapeutics receivables from 2020 to 2024. Receivables can be defined as the total amount of collectibles for a company

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Panbela Therapeutics receivables from 2020 to 2024. Receivables can be defined as the total amount of collectibles for a company

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$141.5B
Gilead Sciences (GILD)	$117.7B
Bristol Myers Squibb (BMY)	$117.6B
Vertex Pharmaceuticals (VRTX)	$105.8B
CSL (CSLLY)	$85.8B
Regeneron Pharmaceuticals (REGN)	$78.8B
GSK (GSK)	$70.7B
Argenex SE (ARGX)	$38.2B
Alnylam Pharmaceuticals (ALNY)	$31.3B
BioNTech SE (BNTX)	$27.3B
Biogen (BIIB)	$21.8B
Illumina (ILMN)	$21.4B
BeiGene (BGNE)	$18B
Moderna (MRNA)	$15.6B
Genmab (GMAB)	$13.6B
Incyte (INCY)	$13.4B
BioMarin Pharmaceutical (BMRN)	$12.8B
Insmed (INSM)	$12.6B
Sarepta Therapeutics (SRPT)	$11.8B
Bio-Techne Corp (TECH)	$11.6B
Vaxcyte (PCVX)	$10.7B
Exact Sciences (EXAS)	$10.6B
QIAGEN (QGEN)	$10.3B
Swedish Orphan Biovitrum (BIOVF)	$9.8B
Exelixis (EXEL)	$9.7B
Bio-Rad Laboratories (BIO.B)	$9.1B
Intra-Cellular Therapies (ITCI)	$9.1B
Roivant Sciences (ROIV)	$8.7B
Ascendis Pharma (ASND)	$8.5B
Repligen (RGEN)	$8.2B